用于糖尿病自我管理支持与共享决策的整合式电子健康系统(POWER2DM)的临床影响:一项随机对照试验
POWER2DM 是一项在荷兰与西班牙开展的随机对照试验,226 例 1 型或 2 型糖尿病患者随机接受 POWER2DM 整合式电子健康系统或常规照护 37 周。POWER2DM 组 HbA1c 从 60.6±14.7 mmol/mol(7.7±1.3%)降至 56.7±12.1 mmol/mol(7.3±1.1%)(p<0.001),常规照护组无变化(p=0.19),组间差异 0.24%(p=0.008)。亚组分析中 2 型糖尿病参与者 HbA1c 下降(p<0.001),1 型糖尿病参与者无变化(p=0.84)。
要点
- POWER2DM 组 HbA1c 较基线下降(p<0.001),常规照护组无变化(p=0.19),组间差异 0.24%(p=0.008)。
- 亚组分析中 2 型糖尿病参与者 HbA1c 下降(p<0.001),1 型糖尿病参与者无变化(p=0.84)。
- 1 型糖尿病参与者生活质量改善(组间差异 p=0.047),两型糖尿病自我管理均改善。
核心结论
- POWER2DM 与常规照护相比改善 2 型糖尿病参与者的 HbA1c,改善 1 型糖尿病参与者的生活质量,改善 1 型与 2 型糖尿病参与者的糖尿病自我管理,且在日常生活中接受度良好。
研究设计与样本
- 在荷兰与西班牙医院门诊糖尿病诊所开展随机对照试验,年龄>18 岁的 1 型或 2 型糖尿病参与者用随机化软件随机分为 POWER2DM 组或常规照护组,干预期 37 周。
- 主要结局为研究结束时(37 周)POWER2DM 组与常规照护组之间 HbA1c 的变化;参与者和临床医生对干预未设盲。
- 共 226 例参与者入组(1 型糖尿病 108 例,2 型糖尿病 118 例);POWER2DM 组 n=111,常规照护组 n=115。
主要发现
- POWER2DM 组 HbA1c 从 60.6±14.7 mmol/mol(7.7±1.3%)降至 56.7±12.1 mmol/mol(7.3±1.1%)(均值±SD,p<0.001),常规照护组无变化(基线 61.7±13.7 mmol/mol、7.8±1.3%;研究结束时 61.0±12.4 mmol/mol、7.7±1.1%;p=0.19),组间差异 0.24%(p=0.008)。
- 亚组分析中 POWER2DM 组 2 型糖尿病参与者 HbA1c 从 62.3±17.3 mmol/mol(7.9±1.6%)降至 54.3±11.1 mmol/mol(7.1±1.0%)(p<0.001),1 型糖尿病参与者 HbA1c 无变化(基线 58.8±11.2 mmol/mol[7.5±1.0%];研究结束时 59.2±12.7 mmol/mol[7.6±1.2%];p=0.84)。
- POWER2DM 组组织间液葡萄糖在 3.0 至 3.9 mmol/l 的时间增加,但临床相关低血糖(组织间液葡萄糖低于 3.0 mmol/l)未增加。
- POWER2DM 组 1 型糖尿病参与者生活质量较常规照护组改善(基线 15.7±3.8;研究结束时 16.3±3.5;组间差异 p=0.047)。
- POWER2DM 组内 1 型糖尿病参与者糖尿病自我管理从 7.3±1.2 改善至 7.7±1.2(p=0.002),2 型糖尿病参与者从 6.5±1.3 改善至 6.7±1.3(p=0.003)。
临床怎么用
- 作者结论认为 POWER2DM 较常规照护改善 2 型糖尿病参与者的 HbA1c,改善 1 型糖尿病参与者的生活质量,改善 1 型与 2 型糖尿病参与者的糖尿病自我管理,且在日常生活中接受度良好。
局限性
- 参与者和临床医生对干预未设盲。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: There is a lack of e-health systems that integrate the complex variety of aspects relevant for diabetes self-management. We developed and field-tested an e-health system (POWER2DM) that integrates medical, psychological and behavioural aspects and connected wearables to support patients and healthcare professionals in shared decision making and diabetes self-management. METHODS: Participants with type 1 or type 2 diabetes (aged >18 years) from hospital outpatient diabetes clinics in the Netherlands and Spain were randomised using randomisation software to POWER2DM or usual care for 37 weeks. This RCT assessed the change in HbA1c between the POWER2DM and usual care groups at the end of the study (37 weeks) as a primary outcome measure. Participants and clinicians were not blinded to the intervention. Changes in quality of life (QoL) (WHO-5 Well-Being Index [WHO-5]), diabetes self-management (Diabetes Self-Management Questionnaire - Revised [DSMQ-R]), glycaemic profiles from continuous glucose monitoring devices, awareness of hypoglycaemia (Clarke hypoglycaemia unawareness instrument), incidence of hypoglycaemic episodes and technology acceptance were secondary outcome measures. Additionally, sub-analyses were performed for participants with type 1 and type 2 diabetes separately. RESULTS: A total of 226 participants participated in the trial (108 with type 1 diabetes; 118 with type 2 diabetes). In the POWER2DM group (n=111), HbA1c decreased from 60.6±14.7 mmol/mol (7.7±1.3%) to 56.7±12.1 mmol/mol (7.3±1.1%) (means ± SD, p<0.001), compared with no change in the usual care group (n=115) (baseline: 61.7±13.7 mmol/mol, 7.8±1.3%; end of study: 61.0±12.4 mmol/mol, 7.7±1.1%; p=0.19) (between-group difference 0.24%, p=0.008). In the sub-analyses in the POWER2DM group, HbA1c in participants with type 2 diabetes decreased from 62.3±17.3 mmol/mol (7.9±1.6%) to 54.3±11.1 mmol/mol (7.1±1.0%) (p<0.001) compared with no change in HbA1c in participants with type 1 diabetes (baseline: 58.8±11.2 mmol/mol [7.5±1.0%]; end of study: 59.2±12.7 mmol/mol [7.6±1.2%]; p=0.84). There was an increase in the time during which interstitial glucose levels were between 3.0 and 3.9 mmol/l in the POWER2DM group, but no increase in clinically relevant hypoglycaemia (interstitial glucose level below 3.0 mmol/l). QoL improved in participants with type 1 diabetes in the POWER2DM group compared with the usual care group (baseline: 15.7±3.8; end of study: 16.3±3.5; p=0.047 for between-group difference). Diabetes self-management improved in both participants with type 1 diabetes (from 7.3±1.2 to 7.7±1.2; p=0.002) and those with type 2 diabetes (from 6.5±1.3 to 6.7±1.3; p=0.003) within the POWER2DM group. The POWER2DM integrated e-health support was well accepted in daily life and no important adverse (or unexpected) effects or side effects were observed. CONCLUSIONS/INTERPRETATION: POWER2DM improves HbA1c levels compared with usual care in those with type 2 diabetes, improves QoL in those with type 1 diabetes, improves diabetes self-management in those with type 1 and type 2 diabetes, and is well accepted in daily life. TRIAL REGISTRATION: ClinicalTrials.gov NCT03588104. FUNDING: This study was funded by the European Union's Horizon 2020 Research and Innovation Programme (grant agreement number 689444).
引用
- Ruissen MM, Torres-Peña JD, Uitbeijerse BS, et al. Clinical impact of an integrated e-health system for diabetes self-management support and shared decision making (POWER2DM): a randomised controlled trial. Diabetologia. 2023. PMID: 37775611. doi:10.1007/s00125-023-06006-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。